Evidence map›Paper›PMID 27008006›Full record

ArticleJournal of cancer research and clinical oncology2016

Her2-neu score as a prognostic factor for outcome in patients with triple-negative breast cancer.

Gilda Schmidt, Christoph Gerlinger, Ingolf Juhasz-Böss, Elmar Stickeler, Achim Rody, Cornelia Liedtke, Pauline Wimberger, Theresa Link, Eberhard Müller, Tanja Fehm and 5 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cancer research and clinical oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Gilda SchmidtDepartment of Obstetrics and Gynaecology, Homburg University Medical Centre, University of Saarland, 66421, Homburg, Germany. gilda.schmidt@uks.eu.
Christoph GerlingerDepartment of Obstetrics and Gynaecology, Homburg University Medical Centre, University of Saarland, 66421, Homburg, Germany.
Ingolf Juhasz-BössDepartment of Obstetrics and Gynaecology, Homburg University Medical Centre, University of Saarland, 66421, Homburg, Germany.
Elmar StickelerDepartment of Obstetrics and Gynaecology, RWTH Aachen University, 52062, Aachen, Germany.
Achim RodyDepartment of Obstetrics and Gynecology, University Clinic of Schleswig-Holstein, Campus Luebeck, 23538, Lübeck, Germany.
Cornelia LiedtkeDepartment of Obstetrics and Gynecology, University Clinic of Schleswig-Holstein, Campus Luebeck, 23538, Lübeck, Germany.
Pauline WimbergerDepartment of Gynecology and Obstetrics, Carl Gustav Carus University Hospital, 01069, Dresden, Germany.
Theresa LinkDepartment of Gynecology and Obstetrics, Carl Gustav Carus University Hospital, 01069, Dresden, Germany.
Eberhard MüllerHospital St. Wendel, 66606, St. Wendel, Germany.
Tanja FehmDepartment of Gynecology and Obstetrics, Duesseldorf University Hospital, 40225, Düsseldorf, Germany.
Manuela AbelHospital Idar-Oberstein, 55743, Idar-Oberstein, Germany.
Stefan SteinHospital Idar-Oberstein, 55743, Idar-Oberstein, Germany.
Rainer BohleDepartment of Obstetrics and Gynaecology, Homburg University Medical Centre, University of Saarland, 66421, Homburg, Germany.
Jan EndrikatDepartment of Obstetrics and Gynaecology, Homburg University Medical Centre, University of Saarland, 66421, Homburg, Germany.
Erich-Franz SolomayerDepartment of Obstetrics and Gynaecology, Homburg University Medical Centre, University of Saarland, 66421, Homburg, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTriple-negative breast cancer (TNBC) is characterized by a strong heterogeneity with regard to tumour biology as well as in the clinical course of the disease. This study aimed to analyse whether there are any prognostic factors enabling prediction of the clinical outcome in patients with TNBC. Particularly, the impact of Her2-neu score 0 versus Her2-neu score 1 and 2 on survival was investigated. MATERIALS AND

methodsWe retrospectively studied a cohort of 1013 patients with TNBC, diagnosed at seven hospitals between May 2002 and February 2015. We studied the impact of Her2-neu scores (0 vs. 1 or 2 with negative FISH) on disease-free survival (DFS) and overall survival (OS).

results1013 patients were included in this study. 447 (44.13 %) of them had a T2-4 tumour. A total of 314 (31.00 %) were nodal-positive and 714 (70.48 %) had high-grade tumours. The Her2-neu score of all participating patients was determined. 588 (58.05 %) of them had a Her2-neu score 0, and 425 (41.95 %) had a score of 1 or 2. This study shows that TNBC patients with a Her2-neu score 0 had a significantly poorer outcome regarding DFS (p = 0.0001) and OS (p = 0.0051) compared to a score of 1 or 2. In contrast, grading did not seem to have any prognostic value for women with TNBC.

conclusionThe Her2-neu score 0 might be considered as an innovative prognostic factor for patients with TNBC indicating poor clinical outcome.

Indexed as

Erb-b2 Receptor Tyrosine KinasesFemaleHumansPrognosisRetrospective StudiesTriple Negative Breast NeoplasmsERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesDFSHer2neu scoreOSTNBC

Identifiers

PMID27008006
PMCPMC11819296

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.